(CBMG) Acquiring Chinese PLA General Hospital’s CAR-T Immuno-Oncology Tech

PALO ALTO, Calif., Feb. 9, 2015  — Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (“CBMG” or the “Company”), a biomedicine company engaged in the development of cellular therapies for degenerative and cancerous diseases, today announced its acquisition of Chinese PLA General Hospital’s (“PLAGH”, Beijing, also known as “301 Hospital”) Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) Immuno-Oncology patents (all pending), and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge.

“This CAR-T cell technology acquisition further accelerates CBMG’s growth in the Immuno-Oncology segment. We look forward to working with PLAGH as a long-term partner as we evaluate paths to commercialization,” commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.

CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors. Wei Dong Han, MD, PhD, head of PLAGH’s Biotherapy Department, is a renowned key opinion leader in the cancer immunotherapy field. Professor Han’s team has conducted several preliminary clinical studies of various CAR-T constructs targeting CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin’s lymphoma and EGFR-HER1-positive advanced lung cancer. PLAGH is a top-ranking medical center in China, holding to the highest academic standards. The hospital consists of 125 clinical, medical and technological departments and 4,000 patient beds, with annual volumes of approximately 4 million patients and more than 65,000 surgeries.

Prior to acquiring PLAGH’s technology, the Company has made progress with recent acquisitions of Agreen Biotech Co. Ltd. and its T-Cell Memory technology (Tcm), T Cell Receptor clonality analysis technology, as well as another third generation CAR-T, anti-PD-1, CD19 and aAPC cancer immunotherapy technologies from Persongen Biotechnology Ltd. Together with PLAGH’s technology, CBMG’s state-of-the art infrastructure and clinical platform, along with these acquired technologies will enable improvement of cancer immune cell therapies and strategic combination therapies which will boost the Company’s Immuno-Oncology presence, and pave the way for future partnerships.

“We are very impressed by the quality of the work done by Dr. Han and his team at PLAGH, and are excited by the safe and efficacious profile of these novel T cell therapies for cancerous diseases, which we deem necessary to be a leader in this field while providing alluring prospective therapies for other cancers. This is the beginning of a long-term strategic partnership between CBMG and PLAGH. Together, we will expeditiously continue our quest in developing safer and more effective cancer immunotherapy programs with leading hospitals and other partners,” said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com

         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 347 481-3711
         vivian.chen@grayling.com

(LFVN) Earns NSF Product Certification

LifeVantage Corporation Flagship Product, Protandim, Passes Globally Recognized Quality Certification Program

SALT LAKE CITY, Feb. 9, 2015  — LifeVantage Corporation (Nasdaq:LFVN), announced that its flagship product, Protandim, has earned certification from NSF International. Recognized by regulatory agencies at the local, state, federal and international level, NSF certification demonstrates that a product complies with all standard requirements for safety, quality, and performance. NSF conducts periodic facility audits and product testing to verify that the product continues to comply with the standard. LifeVantage is continuing to work with NSF International to complete certification for its international formula of Protandim, currently sold in Japan.

“We hold our suppliers, manufacturers, and employees to the highest quality standards,” said LifeVantage Chief Operating Officer, Robert M. Urban. “Earning NSF certification for Protandim is an honor, and helps assure customers worldwide that our product has been tested and certified to be of the highest quality by one of the most respected independent certification organizations in existence today.”

NSF International is dedicated to being the leading global provider of public health and safety-based risk management solutions while serving the interests of all stakeholders, namely the public, the business community and government agencies. The organization has received accreditation from the Occupational Safety and Health Administration (osha.gov), the Standards Council of Canada (SCC) (scc.ca), the American National Standards Institute (ANSI) (ansi.org) and the International Accreditation Service (iasonline.org). NSF laboratories worldwide are ISO/IEC 17025 accredited for testing and calibration.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq:LFVN), is a science based network marketing company that is dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim®, the Nrf2 Synergizer® patented dietary supplement, the TrueScience™ Anti-Aging Skin Care Regimen, Canine Health, and the AXIO™ energy product line.  LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.

CONTACT: Company Relations Contact:

         John Genna (801) 432-9172
         Vice President of Communications &
         Corporate Partnerships

         Investor Relations Contacts:
         Cindy England (801) 432-9036
         Director of Investor Relations
         -or-
         John Mills (646) 277-1254
         Partner, ICR INC

(MATR) Provides Update on Q4 Bookings and Book of Business

(ATOS) National Distribution Agreement With Thermo Fisher Scientific

(QTWW) Expects to Report Strong Sequential Q4 Product Revenue Growth

– Fourth quarter product sales expected to approximately double the third quarter level reported – Overall fourth quarter revenues expected between $12 million and $13 million – Sequential product growth driven by continued execution of storage systems strategy – Strong revenues complemented by solid order flow – product backlog anticipated to increase during fourth quarter by approximately $3 million to $17.8 million – Expect strong overall revenue growth in 2015

LAKE FOREST, Calif., Feb. 9, 2015  — Quantum Fuel Systems Technologies Worldwide, Inc. (NASDAQ: QTWW), a leader in natural gas storage systems, integration, and vehicle system technologies, today announced that it expects to report strong sequential revenue growth for its fourth quarter ending December 31, 2014.  Product sales for the fourth quarter are anticipated to approximately double relative to the level reported for the third quarter of 2014 due to strong customer demand for its natural gas fuel storage systems.  The Company also anticipates that it will report a robust product backlog of approximately $17.8 million at December 31, 2014 which is approximately $3 million higher than the $14.8 million the Company reported for the end of the third quarter.  The Company also expects to report a moderate improvement in its loss from continuing operations for the fourth quarter as compared to the third quarter which is driven primarily by increased product revenues and improved product margins. Finally, the Company believes that overall revenues will grow approximately 40% to 50% in 2015 based on existing and anticipated orders from its growing customer base and that related product margins will continue to improve during this period.

“We continue to experience traction in the industry as we effectively execute on our fuel storage systems strategy and we are excited to finish the year with anticipated strong sequential revenue growth and burgeoning order flow,” said Brian Olson, President and CEO of Quantum. “We began the process of fully implementing the systems strategy in the second half of 2014 and we believe we will recognize more revenues from our systems during this six-month period, basically right out of the gate, than we recognized on stand-alone tank sales during the first half of 2014.  We understand that the market was and remains concerned about the lost tank sales from a former key customer when we announced our direction into storage systems, but we have in a very short period demonstrated our ability to grow our customer base with our systems strategy,” concluded Mr. Olson.

In May 2014, Quantum announced its strategic direction to service the heavy duty OEM market segment, in addition to other market segments, with natural gas fuel storage systems. During 2014, Quantum brought to market its innovative, light-weight Q-Rail^LITE™ and Q-Cab^LITE™ CNG storage modules which are integrated CNG fuel systems for heavy-duty truck applications. Each storage module contains Quantum’s proprietary, ultra-light Q-Lite^® CNG storage cylinders, which further minimizes weight and increases fuel capacity.

The Company anticipates that it will finalize its results from operations for the three and twelve month periods ended December 31, 2014, subject to the review and completion of the audit of the twelve-month period ended December 31, 2014 by the Company’s auditors, and hold a conference call to discuss its 2014 financial results in early March.

About Quantum: Quantum Fuel Systems Technologies Worldwide, Inc. is a leader in the innovation, development and production of natural gas fuel storage systems and the integration of vehicle system technologies including engine and vehicle control systems and drivetrains. Quantum produces innovative, advanced, and lightweight compressed natural gas storage tanks and supplies these tanks, in addition to fully-integrated natural gas storage systems, to truck and automotive OEMs and aftermarket and OEM truck integrators. Quantum provides low emission and fast-to-market solutions to support the integration and production of natural gas fuel and storage systems, hybrid, fuel cell, and specialty vehicles, as well as modular, transportable hydrogen refueling stations. Quantum is headquartered in Lake Forest, California, and has operations and affiliations in the United States, Canada, and India.

Forward Looking Statements: This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding anticipated fourth quarter 2014 revenues, product sales, growth in product backlog, revenues from system sales relative to tank sales in 2014, improvement in net operating loss, improvement in product margins, anticipated revenues in 2015, and the timing for release of the 2014 financial results.  All statements included in this report, other than those that are historical, are forward looking statements and can generally be identified by words such as “may,” “could,” “will,” “should,” “assume,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “predict,” “estimate,” “forecast,” “outlook,” “potential,” or “continue,” or the negative of these terms, and other comparable terminology. Various risks and other factors could cause actual results, and actual events that occur, to differ materially from those contemplated by the forward looking statements. Risk factors include the cancellation of orders, the acceptance of the Company’s products, and the other risk factors contained in our annual report on Form 10-K for the year ended December 31, 2013 and our interim reports on Form 10-Q for the first three quarters of 2014. Except as may be required by applicable law, the Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

More information about the products and services of Quantum can be found at http://www.qtww.com/ or you may contact:

Quantum Investor Relations
Phone:  949-399-4555
Email:  ir@qtww.com

(PESI) to Present at The Brewer Group Innovations Conference

(TEAR) Announces Inducement Grant Under NASDAQ Rule 5635(c)(4)

SAN DIEGO, Feb. 6, 2015  — TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced that on February 5, 2015, a majority of the independent members of the Company’s Board of Directors approved the grant of an option to purchase 100,000 shares of the Company’s common stock to Raymond Kong, the Company’s Vice President of Sales. The stock option has a ten-year term and a per share exercise price equal to the higher of (i) the closing price per share of the Company’s common stock as quoted on the Nasdaq Capital Market on February 5, 2015 or (ii) the prior five-day volume weighted average price of the Company’s common stock as quoted on the Nasdaq Capital Market at the close of business on February 5, 2015. The stock option has a vesting commencement date of February 5, 2015, and will vest in equal annual increments over a three year period, subject to Mr. Kong’s continued service with the Company through each applicable vesting date. In addition, the stock option will fully accelerate as to vesting in the event of a change of control prior to Mr. Kong’s termination of service. The stock option grant was made as an inducement that was material to Mr. Kong’s acceptance of employment with the Company and was granted as an employment inducement award pursuant to NASDAQ Listing Rule 5635(c)(4).

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation’s common shares trade on the NASDAQ Capital Market under the symbol ‘TEAR’ and on the Toronto Stock Exchange under the symbol ‘TLB’.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding the future potential of the TearLab Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT: Stephen Kilmer
         (647) 872-4849
         skilmer@tearlab.com

(CME) CFO John Pietrowicz to Present at Credit Suisse Forum February 11

CHICAGO, Feb. 6, 2015  — CME Group announced today that Chief Financial Officer John Pietrowicz will present at the 16^th Annual Credit Suisse Financial Services Forum, in Miami, Florida, on Wednesday, February 11, 2015, at 8:45 a.m. (Eastern Time).

The presentations will be broadcast live over the Internet and can be accessed via the exchange’s web site at http://investor.cmegroup.com.  Please allow extra time prior to the presentation to visit the site and download the streaming media software required to listen to the Internet broadcast.  An audio Webcast will be available for replay at the same address approximately 24 hours following the conclusion of the conference.

As the world’s leading and most diverse derivatives marketplace, CME Group (www.cmegroup.com) is where the world comes to manage risk. CME Group exchanges offer the widest range of global benchmark products across all major asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. CME Group brings buyers and sellers together through its CME Globex® electronic trading platform, its trading facilities in New York and Chicago, and through its London-based CME Europe derivatives exchange.  CME Group also operates one of the world’s leading central counterparty clearing providers through CME Clearing and CME Clearing Europe, which offer clearing and settlement services across asset classes for exchange-traded contracts and over-the-counter derivatives transactions.  These products and services ensure that businesses everywhere can substantially mitigate counterparty credit risk.

CME Group is a trademark of CME Group Inc. The Globe Logo, CME, Globex and Chicago Mercantile Exchange are trademarks of Chicago Mercantile Exchange Inc.  CBOT and the Chicago Board of Trade are trademarks of the Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are registered trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc.  All other trademarks are the property of their respective owners. Further information about CME Group (NASDAQ: CME) and its products can be found at www.cmegroup.com.

(UUUU) to Resume Development at High-Grade Canyon Uranium Mine

– Energy Fuels is preparing to resume development at its high-grade Canyon mine, located in northern Arizona – The Canyon mine contains 1.63 million pounds of U3O8 with an average grade of 0.98% – Ore production at the Pinenut mine continues to meet expectations in terms of total tonnage mined, ore grade and pounds of U3O8 recovered – Energy Fuels is clearly emerging as the dominant mining company focused on U.S. uranium production by adding ISR production through its pending acquisition of Uranerz Energy Corporation

Energy Fuels Inc.
Curtis Moore
Investor Relations
(303) 974-2140 or Toll free: 1-888-864-2125
investorinfo@energyfuels.com
www.energyfuels.com

(UEPS) Provides Further Update on SASSA Tender Process

JOHANNESBURG, SOUTH AFRICA–(February 06, 2015) – Net1 (NASDAQ: UEPS) (JSE: NT1) today provided a further update on the SASSA tender process.

As reported in the press release dated December 5, 2014, the Company filed further affidavits on January 20, 2015 and written submissions on January 27, 2015 with the South African Constitutional Court (“Court”), setting out the Company’s reasons and arguments for a Court order setting aside the Request For Proposal (“RFP”) and / or directing SASSA to issue a corrected RFP.

The Court issued further directions today by instructing SASSA to indicate to the Court by Tuesday, February 10, 2015 whether it intends to make further amendments to the RFP and, if so, to effect such changes by Friday, February 13, 2015. The Court indicated that further directions may be issued.

About Net1 (www.net1.com)
Net1 is a leading provider of alternative payment systems that leverage its Universal Electronic Payment System (“UEPS”), to facilitate biometrically secure, real-time electronic transaction processing to unbanked and under-banked populations of developing economies around the world in an online or offline environment. Net1’s UEPS/EMV solution is interoperable with global EMV standards that seamlessly permit access to all the UEPS functionality in a traditional EMV environment. In addition to payments, UEPS can be used for banking, healthcare management, payroll, remittances, voting and identification.

Net1 operates market-leading payment processors in South Africa and the Republic of Korea. In addition, Net1’s proprietary MVC technology offers secure mobile payments and banking services in developed and emerging countries.

Net1 has a primary listing on the NASDAQ and a secondary listing on the Johannesburg Stock Exchange.

Investor Relations Contact:
Dhruv Chopra
Head of Investor Relations
Phone: +1-917-767-6722
Email: dchopra@net1.com

(VBLT) Receives European Patent Issuance on Lecinoxoid Platform Technology

TEL AVIV, Israel, Feb. 6, 2015  — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases, today announced the issuance by the European Patent Office (EPO) of Patent No. 2348866, entitled “Oxidized Lipid Compounds and Uses Thereof” and covering the compound, pharmaceutical composition, and use of the Company’s second generation oral Lecinoxoids. VBL is currently applying its Lecinoxoid technology to anti-inflammatory indications, including psoriasis and ulcerative colitis. This patent provides intellectual property rights in validated European countries through 2029.

“This granted patent is an important addition to VBL’s Lecinoxoids intellectual property portfolio, which now includes more than 70 issued patents and pending patent applications worldwide,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “VBL is committed to continuing to expand and strengthen our pipeline through multiple layers of intellectual property protection. We look forward to leveraging our second-generation molecules to additional immune-inflammatory indications in broad patient populations.”

VBL recently completed two Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound, VB-201, for the treatment of psoriasis and ulcerative colitis. Top line results from both studies are expected in the first quarter of 2015.

About the Lecinoxoid Platform:

VBL’s proprietary Lecinoxoid platform technology comprises a family of orally administered small molecules designed to modulate the body’s inflammatory response. Lecinoxoids are compounds that are structurally and functionally similar to naturally occurring molecules, known as oxidized phospholipids, which possess immune modulating anti-inflammatory properties, modified to enhance stability and activity. The Lecinoxoid platform technology seeks to harness the ability of oxidized phospholipids to regulate and attenuate key immune-inflammatory signaling.

Lecinoxoids have the potential to act on two specific mechanisms: the inhibition of cellular signaling cascades associated with the innate immune system, known as toll-like receptor signaling, and the inhibition of the migration of monocytes toward chemoattractants present in areas of inflammation.

About VBL:

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics’ clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body’s natural physiologic and genetic regulatory elements. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in the first half of 2015, under a special protocol assessment agreement granted by the FDA. VBL Therapeutics’ lead product candidate from its anti-inflammatory program, VB-201, is an oral small molecule which recently completed Phase 2 clinical trials for psoriasis and for ulcerative colitis, with top-line results expected in the first quarter of 2015.

Forward Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Hannah Deresiewicz
         Stern Investor Relations, Inc.
         212-362-1200, hannahd@sternir.com

(LNCO) SEC Closes Inquiry of LINN Energy

HOUSTON, Feb. 5, 2015  — LINN Energy, LLC (Nasdaq:LINE) (“LINN”) and LinnCo, LLC (Nasdaq:LNCO) (“LinnCo” and together with LINN, the “Company”) announced today that the Fort Worth Regional Office of the Securities and Exchange Commission (“SEC”) has formally notified LINN that the SEC has closed its inquiry and does not intend to recommend any enforcement action against the Company.

“After a thorough and lengthy process, we are clearly very pleased with this excellent outcome,” said Mark E. Ellis, Chairman, President and Chief Executive Officer.

On July 1, 2013, LINN and LinnCo voluntarily disclosed the SEC’s informal inquiry. LINN and LinnCo cooperated fully with the SEC during its inquiry.

ABOUT LINN ENERGY

LINN Energy’s mission is to acquire, develop and maximize cash flow from a growing portfolio of long-life oil and natural gas assets. LINN Energy is a top-15 U.S. independent oil and natural gas development company, with approximately 7.8 Tcfe of proved reserves (pro forma for announced 2014 trades, acquisitions and divestitures) in producing U.S. basins as of December 31, 2013. More information about LINN Energy is available at www.linnenergy.com.

ABOUT LINNCO

LinnCo was created to enhance LINN Energy’s ability to raise additional equity capital to execute on its acquisition and growth strategy. LinnCo is a Delaware limited liability company that has elected to be taxed as a corporation for United States federal income tax purposes, and accordingly its shareholders will receive a Form 1099 in respect of any dividends paid by LinnCo. More information about LinnCo is available at www.linnco.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This press release includes “forward-looking statements.” All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements include, but are not limited to forward-looking statements about acquisitions, divestitures and trades, timing and payment of distributions, and the expectations of plans, strategies, objectives and anticipated financial and operating results of the company, including the company’s drilling program, production, hedging activities, capital expenditure levels and other guidance included in this press release. These statements are based on certain assumptions made by the company based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. These include risks relating to the company’s financial performance and results, availability of sufficient cash flow to pay distributions and execute its business plan, prices and demand for oil, natural gas and natural gas liquids, the ability to replace reserves and efficiently develop current reserves and other important factors that could cause actual results to differ materially from those projected as described in the company’s reports filed with the Securities and Exchange Commission. See “Risk Factors” in the company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other public filings and press releases.

Any forward-looking statement speaks only as of the date on which such statement is made and the company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: LINN ENERGY, LLC

         Investors & Media:

         Clay Jeansonne - Vice President - Investor Relations
         281-840-4193

         Sarah Nordin - Public Relations & Media
         713-904-6605

(GPRO) Channel Coming to Roku Streaming Platform

World’s Most Engaging User Generated Content Coming to Millions of Roku Customers

SAN MATEO, Calif., Feb. 5, 2015  — GoPro, Inc. (NASDAQ:GPRO), enabler of some of today’s most engaging content, today announced that it will launch a GoPro Channel on the Roku® streaming platform this spring. The custom-designed streaming channel will be a one-stop video destination that delivers on-demand GoPro content to millions of Roku customers.

With this agreement, Roku joins GoPro’s expanding roster of distribution partners including Xbox, LG and Virgin America.

“GoPro content is unique in that it emotionally resonates with a global audience,” said Adam Dornbusch, Head of Programming at GoPro. “The GoPro channel will make it simple for Roku customers to watch GoPro originally-produced and “best of” user-generated content on their televisions at home. We are excited to bring the world of GoPro to Roku customers as they are one of the most engaged customer bases when it comes to the amount of streaming content they view.”

When it launches on the Roku platform, the GoPro streaming channel will include:

• Featured playlists: Explore content from Deep Sea to Full Throttle
• Favorite videos: Readily access favorites and recently watched content
• Product Discovery: Learn which GoPro products were used to “get the shot”

“We’re incredibly excited to bring the action-packed videos created by the GoPro community to the Roku streaming platform,” said Ed Lee, vice president of content at Roku. “Roku delivers an experience that our customers truly love, and I know that they’re going to be captivated by the inspiring new content available to them with the launch of the GoPro channel this spring.”

To view content similar to what will air on the GoPro channel for the Roku platform, visit the GoPro Channel on YouTube. For more information on GoPro and its HERO line of cameras and accessories, visit GoPro.com.

About GoPro, Inc. (NASDAQ:GPRO)

GoPro, Inc. is transforming the way consumers capture, manage, share and enjoy meaningful life experiences. We do this by enabling people to capture engaging, immersive photo and video content of themselves participating in their favorite activities. Our customers include some of the world’s most active and passionate people. The quality and volume of their shared GoPro content, coupled with their enthusiasm for our brand, virally drives awareness and demand for our products.

What began as an idea to help athletes document themselves engaged in their sport has become a widely adopted solution for people to document themselves engaged in their interests, whatever they may be. From extreme to mainstream, professional to consumer, GoPro has enabled the world to capture and share its passions. And in doing so, the world, in turn, is helping GoPro become one of the most exciting and aspirational companies of our time.

For more information, visit www.gopro.com or connect with GoPro on YouTube, Twitter, Facebook, Pinterest or LinkedIn.

GOPRO® and HERO® are trademarks or registered trademarks of GoPro Inc. in the United States and other countries.

Roku is a registered trademark of Roku, Inc. in the U.S. and in other countries.

(APDN) Completes DNA Marking of 10,000 Bales of American Pima Cotton

SigNature(R) T DNA Campaign Supports Global Supply Chain Integrity for Cotton Textiles and Apparel Industries

(SMRT) Reports January Comparable Store Sales Increase of 6.6%

Fourth Quarter: Total Sales Increased 7.3% and Comparable Store Sales Increased 5.6%

JACKSONVILLE, Fla., Feb. 5, 2015  — Stein Mart, Inc. (Nasdaq:SMRT) today reported sales for the four weeks of January.

Geographically, the Midwest, Southeast and Gulf States had the strongest sales in January, while the West, Northeast and Florida had comparable store sales increases, but performed lower than the chain. For the fourth quarter, ladies’ apparel and home had the strongest sales, while accessories and men’s performed lower than the chain. The Company operated 270 stores at the end of January this year compared to 264 stores last year.

“Our fourth quarter 5.6 percent comparable store sales increase capped off a great second-half performance,” said Jay Stein, Chief Executive Officer. “Sales continued to build throughout the quarter, particularly as we did not have a repeat of last year’s severe weather events.”

Fourth Quarter and Fiscal 2014 Financial Results

Financial results for the fourth quarter and fiscal 2014 will be reported prior to the opening of the U.S. financial markets on Thursday, March 12, 2015. Management will also hold a conference call at 10:00 a.m. ET that morning to discuss those results. The call may be heard on the Company’s investor relations website at http://ir.steinmart.com. A replay of the conference call will be available on the website through March 31, 2015.

About Stein Mart

Stein Mart stores offer the fashion merchandise, service and presentation of a better department or specialty store, at prices competitive with off-price retail chains. With locations from California to Massachusetts, as well as steinmart.com, Stein Mart’s focused assortment of merchandise features current season, moderate to better fashion apparel for women and men, as well as accessories, shoes and home fashions. In 2014, Stein Mart was voted America’s “Best Department Store” by readers of USA TODAY.

SMRT-S

Additional information about Stein Mart, Inc. can be found at www.steinmart.com

CONTACT: Linda L. Tasseff
         Director, Investor Relations
         (904) 858-2639
         ltasseff@steinmart.com

(ROKA) Strengthens Management Team to Drive Growth

Appoints Mary Duseau as Chief Commercial Officer

WARREN, N.J., Feb. 5, 2015  — Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced that Mary Duseau has been named Senior Vice President and Chief Commercial Officer, reporting to Paul Thomas, President and Chief Executive Officer.

“I am pleased to announce the addition of Mary Duseau to our senior management team,” said Paul Thomas.  “Ms. Duseau has a distinguished background in commercial leadership and brings a level of experience and talent that we expect will help drive growth in our business and capitalize on opportunities for Roka to become a leader in the food safety testing market.”

Ms. Duseau brings more than 25 years of sales and marketing experience to her role as Chief Commercial Officer, most recently serving as Global Sales Director at Andor Technologies, a division of Oxford Instruments.  Prior to joining Andor Technologies, Ms. Duseau held various sales and management roles of increasing responsibility with Perkin Elmer from 2000 through 2012.

About Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result-out” Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit http://rokabio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the “Exchange Act”). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we “believe”, “expect”, “anticipate”, “plan” and similar expressions) that are not statements of historical fact should be considered forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission.  Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Investor Contact:
Roka Bioscience, Inc.
ir@rokabio.com
855-ROKABIO (855-765-2246)
Source: Roka Bioscience

(EAC) Announces Organizational Restructuring

Erickson Incorporated (NASDAQ:EAC) announced today that it has initiated a comprehensive organizational restructuring that it anticipates will create significant new efficiencies and cost reductions, improve profitability, and enhance the Company’s overall competitive position. The Company will now be organized into the following four business segments:

• Government Aviation Services, led by Chris Bassett
• Oil & Gas Aviation Services, led by Santiago Crespo
• Commercial Aviation Services, led by Andy Mills
• Manufacturing & MRO, led by Kerry Jarandson

This significant restructuring marks the final stage of integration associated with the Evergreen Helicopters and Air Amazonia acquisitions. In connection with its business segment realignment, the Company is engaged in several operational initiatives that are focused on achieving substantial efficiency and accountability improvements across the business and are intended to enhance the Company’s overall profitability and cash flow position.

As part of the planned restructuring, Erickson will lay off approximately 150 employees. The layoffs will impact field, factory, and office locations, primarily in Oregon, but also at other U.S. locations.

”We value our team members deeply and have been fortunate to build an organization that has demonstrated exceptional quality and commitment,” said Udo Rieder, Erickson President and CEO. “This restructuring will create efficiency, reduce our costs, simplify lines of reporting and responsibility and enhance accountability. We believe we will be better able to address the challenges we have seen in our end markets, particularly in Defense and Oil & Gas, and reinforce our position as one of the world’s leading aviation services providers.”

About Erickson

Erickson is a leading global provider of aviation services specializing in oil and gas, government services, legacy aircraft MRO and manufacturing, and commercial services such as firefighting, HVAC, power line, specialty, construction, and timber harvesting. Erickson operates a fleet of 86 rotary-wing (light, medium, and heavy) and fixed-wing aircraft, including 20 heavy-lift S-64 Aircranes. Founded in 1971, Erickson is headquartered in Portland, Oregon, USA, and maintains operations in North America, South America, Europe, the Middle East, Africa, Asia Pacific, and Australia. For more information, please visit www.ericksonaviation.com.

This press release contains certain statements relating to future results (including, without limitation, “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict”), which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on beliefs of Company management, as well as assumptions and estimates based on information currently available to the Company, and are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated, including our inability to successfully execute on our business restructuring goals and also including certain other risks or uncertainties more fully described under the heading “Risk Factors” in our most recently filed Annual Report on Form 10-K as well as in the other reports we file with the SEC from time to time, which are available at the SEC’s web site located at http://www.sec.gov. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

(OHRP) Announces Proposed Public Offering of Common Stock

NEW YORK, Feb. 5, 2015  — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it intends to offer its common stock in an underwritten public offering. Ohr Pharmaceutical also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering to cover overallotments, if any. Ohr Pharmaceutical plans to use the net proceeds from the offering to fund clinical trials of OHR-102, the development of its pre-clinical pipeline and for general corporate purposes.

Cowen and Company, LLC is acting as the sole book running manager. LifeSci Capital, LLC is acting as co-manager of the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ohr intends to offer and sell these securities pursuant to a shelf registration statement on Form S-3 (File No. 333-201368) filed with the Securities and Exchange Commission (“SEC”) on January 5, 2015 and declared effective on January 21, 2015.  A preliminary prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140). An electronic copy of the prospectus supplement and accompanying documents relating to the offering is available on the SEC website at www.sec.gov.

Before investing in the offering, you should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Ohr has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about Ohr and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company’s lead product, Squalamine, is currently being studied as an eye drop formulation (OR-102) in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program. Additional information on the company may be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr’s most recent filings with the SEC discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

CONTACT: Investor Relations
         888-388-2327
         ir@ohrpharmaceutical.com

         LifeSci Advisors, LLC
         Michael Wood
         646-597-6983
         mwood@lifesciadvisors.com

(VSTA) Dr. Gerard Sanacora Joins VistaGen’s Clinical and Scientific Advisory Board

Yale Depression Expert to Advise on Late-Stage Development of Orally-Active AV-101 for Major Depressive Disorder

(SOFO) Cited as a Leader in Enterprise Video Platforms and Webcasting

Sonic Foundry, Inc. (NASDAQ: SOFO), the trusted global leader for video creation and management solutions, has been cited as a leader in The Forrester Wave™: Enterprise Video Platforms and Webcasting, Q1 2015.

Sonic Foundry was among the select companies that Forrester Research, Inc. invited to participate in its report. In this evaluation the company was cited as a leader in all three of the report’s categories —‘Webcasting,’ ‘Portals’ and the combined, comprehensive solution ‘Webcasting and Portals.’

The report, authored by Phillip Karcher, senior analyst, assesses 16 enterprise video platform and webcasting providers based on their current offerings, strategies and market presence.

“Video is becoming a more common channel that enterprises use to communicate — both internally with other employees and externally with customers and partners,” according to the report. “As enterprises look at applications for video across marketing, corporate communications, and training, selecting the right technology platform is an important decision … Selecting the right platform allows application development and delivery pros to maximize their opportunity to apply video communications to achieve organizational objectives and enhance customer and employee experiences.”

According to the report, Leaders have the following characteristics:

• A strong track record in the webcasting space, with interactive and customizable webcasting player experience, robust control platform to manage webcasts like staged events and tools to edit recordings
• Excellent portal features for video content management, uploading and encoding and workflow; supporting many options for video capture and good video editing tools
• Having the most complete offerings for organizations that want a multipurpose solution for webcasting and video portals

Sonic Foundry was also cited for:

• Webcasting player with in-video search and ability to show multiple camera feeds at once
• Portal and content management capabilities
• Desktop content creation tools
• Ability to ingest web conferencing recordings
• Cloud-based videoconferencing signal acquisition
• Restful API commitment

“We’re very pleased to be recognized by Forrester’s respected analysts. We believe that our status as a leader in this report solidly establishes Mediasite as a recognized solution for comprehensive video content management for the enterprise,” said Gary Weis, Sonic Foundry CEO. “We know what’s required for scalable, widespread adoption of content creation and management, having successfully helped more than 3,000 customers. We will continue to innovate best-in-class technologies for the knowledge workers of the future.”

Download the Forrester Wave: Enterprise Video Platforms and Webcasting, Q1 2015 report at www.sonicfoundry.com/ForresterWave.

About Sonic Foundry®, Inc.

Sonic Foundry (NASDAQ: SOFO) is the trusted global leader for video capture, management and webcasting solutions in education, business and government. The patented Mediasite Enterprise Video Platform transforms communications, training, education and events for more than 3,000 customers in over 60 countries. The company empowers organizations to reach everyone through the power of video; accelerating knowledge-sharing, preserving valuable content, building stronger teams and getting results. Sonic Foundry is the leader in Aragon Research’s Globe for Video Content Management, Frost & Sullivan’s lecture capture leader for seven consecutive years, a leader in Forrester’s Enterprise Video Platforms and Webcasting Wave and a challenger in Gartner’s Magic Quadrant for enterprise video content management.

© 2015 Sonic Foundry, Inc. Product and service names mentioned herein are the trademarks of Sonic Foundry, Inc. or their respective owners.

(SLAB) Advises Bluegiga on Its Sale to Silicon Labs

— M&A transaction in the Internet of Things ecosystem advised by leading global M&A technology advisor, Mooreland Partners

LONDON, Feb. 4, 2015  — Mooreland Partners (http://www.moorelandpartners.com), the leading global technology-focused M&A advisory firm, today announced that it has acted as the sole financial advisor to Bluegiga on its sale to Silicon Labs. The acquisition of Bluegiga, which offers market-leading wireless solutions to a wide variety of Internet of Things (IoT) applications and markets, further strengthens Mooreland’s position among the most active advisors to the electronics and industrial technologies sector.

“The Bluegiga transaction confirms that IoT continues to be a highly strategic area,” said Peter Globokar, Managing Director in Mooreland’s European office.” This is also an important transaction that sees a leading semiconductor vendor invest in the IoT module arena,” added Charlie Bullock, Managing Director in Mooreland’s Silicon Valley office.

Bluegiga provides high-performance short-range wireless modules and integrated software stacks, developing and selling a range of feature-rich Bluetooth, Bluetooth Smart-Ready, Bluetooth Smart and Wi-Fi solutions for short-range connectivity applications across IoT. The Company’s modules and proprietary software stacks combine seamlessly, resulting in easy-to-use products that have been rapidly designed-in and used by over 1,500 customers historic and current worldwide, many of them global tier-1 OEMs. Bluegiga’s products are integrated into a wide range of OEM products in multiple markets including industrial, commercial, consumer, automotive, retail (iBeacon and POS), residential, and health and fitness. Bluegiga was founded in 2000 and is headquartered in Espoo, Finland, with sales offices in China and the U.S.

Silicon Labs (NASDAQ: SLAB) is a leading provider of silicon, software and system solutions for the Internet of Things, Internet infrastructure, industrial automation, consumer and automotive markets. The Company provides customers with significant advantages in performance, energy savings, connectivity and design simplicity. Backed by a world-class engineering teams with strong software and mixed-signal design expertise, Silicon Labs empowers developers with the tools and technologies they need to advance quickly and easily from initial idea to final product. Mooreland Partners is well positioned as an international technology-focused M&A firm to advise on the growing number of cross-border M&A transactions. According to a recent article in the Financial Times, “In the first nine months of 2014, the value of M&A is nearly two-thirds higher than it was in the same period in 2013, at $2.66tn – a level of activity not seen since 2008.”

ABOUT MOORELAND PARTNERS
Founded in 2002, Mooreland Partners is a leading independent investment bank providing M&A and private capital advisory services to the global technology industry, serving clients from its offices in Silicon Valley, Greenwich (CT), and London. Mooreland’s team of almost 50 banking professionals delivers industry domain and transaction expertise across all major technology sectors including communications technology, mobile and digital media, enterprise software and services, as well as industrial technology and electronics. Follow us on Twitter @MoorelandGlobal or learn more at www.moorelandpartners.com.

All trademarks contained herein are the property of their respective owners.

(CANF) Completes Phase II/III Trial for CF101 in Treatment of Psoriasis

Data expected to be released in Q1 2015

PETACH TIKVA, Israel, Feb. 4, 2015 — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company’s drug candidate CF101 have completed the study’s 32 week treatment protocol. The trial has been completed and the final data is ready for analysis. The Company plans to publish top line results by the end of March 2015.  Interim results from this Phase II/III trial and final results from the prior Phase II trial for CF101 in psoriasis were both positive.

“Following a thorough analysis of the data over the coming weeks, we look forward to announcing top line results on the efficacy and safety of CF101 in the treatment of moderate-to-severe plaque psoriasis. If these results are in line with the previously published favorable interim data, then we believe CF101 could offer a much-needed treatment alternative to patients living with psoriasis,” stated Can-Fite CEO Dr. Pnina Fishman.

The psoriasis therapeutic market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential side effects. According to Global Data, the psoriasis treatment market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018.

This Phase II/III double-blind, placebo-controlled study is designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. Can-Fite enrolled 326 patients through 17 clinical centers in the U.S., Europe, and Israel. The first study cohort was comprised of three arms with patients receiving: 1 mg of CF101; 2 mg of CF101; and placebo. All patients receiving placebo were switched to either 1 mg or 2 mg of CF101 after 12 weeks. The primary efficacy endpoints are a statistically significant improvement in standard measures used by dermatologists to assess psoriasis including the Psoriasis Area Sensitivity Index (PASI) score and the secondary end points among others are the Physicians’ Global Assessment (PGA) score as well as various safety parameters.

About Psoriasis

Psoriasis is a skin condition that affects 2% to 3% of the general population according to the National Psoriasis Foundation. The disease is manifested by scaly plaques on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. Topical agents are typically used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. For moderate to severe cases, systemic biologic drugs, delivered via IV, have dominated the market. According to the National Psoriasis Foundation, common side effects of biologics include respiratory infections, flu-like symptoms, and injection site reactions while rare side effects include serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, blood disorders, and certain types of cancer. We believe a significant need remains for novel oral and safe drugs for patients who do not respond to existing therapies or for whom these therapies are unsuitable.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. CF101 is currently developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (completed Phase II) and psoriasis (Phase II/III).

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is in Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. The Company’s CF602 has shown efficacy in the treatment of erectile dysfunction. Can-Fite has initiated a full pre-clinical program for CF602 in preparation for filing an IND with the U.S. FDA in this indication.  These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with the TASE.  In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114

(SMRT) Announces Special Dividend and $275 Million Credit Facility

JACKSONVILLE, Fla., Feb. 4, 2015  — Stein Mart, Inc. (Nasdaq:SMRT) announced today that its Board of Directors declared a special dividend of $5.00 per common share, payable on February 27, 2015 to shareholders of record as of the close of business on February 13, 2015. The aggregate amount of payment to be made in connection with this special dividend will be approximately $230 million. The special dividend will be funded by existing cash and the credit facilities discussed below. It is the Company’s intent to continue its regular quarterly cash dividend of $0.075 per share.

Stein Mart also announced that it has entered into a second amended and restated credit agreement (the “Credit Agreement”) with Wells Fargo Bank that will mature in February 2020 and a master loan agreement with Wells Fargo Equipment Finance, Inc. (the “Equipment Term Loan” and, together with the Credit Agreement, the “Credit Facilities”). The Credit Facilities replace the Company’s former $100 million senior secured revolving credit facility which was set to mature on February 28, 2017. The Credit Facilities (i) increase the revolving credit facility to $250 million, (ii) add a $25 million equipment term loan that matures 36 months following date of disbursement, (iii) provide better pricing terms, and (iv) extend the maturity date of the former revolving credit facility. Borrowings under the Credit Facilities will primarily be used for a special dividend, but may also be used for working capital, capital expenditures and general corporate purposes.

After payment of the dividend, the Company’s debt will fluctuate between approximately $150 and $200 million in 2015 based on seasonal working capital needs. Interest expense for 2015 is estimated to be approximately $3.5 to $4.0 million based on current interest rates.

“Today’s announcement of a $5.00 special dividend reflects our continued generation of strong cash flows and favorable access to the credit markets which allow us to return value to our shareholders,” said Jay Stein, Chief Executive Officer. “Even after this special dividend, we will have ample capital capacity to make long-term investments in our business, such as our accelerated store expansion.”

About Stein Mart

Stein Mart stores offer the fashion merchandise, service and presentation of a better department or specialty store, at prices competitive with off-price retail chains. With locations from California to Massachusetts, as well as steinmart.com, Stein Mart’s focused assortment of merchandise features current season, moderate to better fashion apparel for women and men, as well as accessories, shoes and home fashions. In 2014, Stein Mart was voted America’s “Best Department Store” by the readers of USA TODAY.

Cautionary Statement Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this release may be forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company does not assume any obligation to update or revise any forward-looking statements even if experience or future changes make it clear that projected results expressed or implied will not be realized. Forward-looking statements involve known and unknown risks and uncertainties that may cause Stein Mart’s actual results in future periods to differ materially from forecasted or expected results. Those risks include, without limitation:

• consumer sensitivity to economic conditions
• competition in the retail industry
• changes in consumer preferences and fashion trends
• ability to negotiate acceptable lease terms with current and potential landlords
• ability to successfully implement strategies to exit under-performing stores
• extreme and/or unseasonable weather conditions
• adequate sources of merchandise at acceptable prices
• dependence on certain key personnel and ability to attract and retain qualified employees
• increases in the cost of employee benefits
• disruption of the Company’s distribution process
• information technology failures
• data security breaches
• acts of terrorism
• ability to adapt to new regulatory compliance and disclosure obligations
• material weaknesses in internal control over financial reporting
• other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission.

SMRT-F

Additional information about Stein Mart, Inc. can be found at www.steinmart.com

CONTACT: For more information:
         Linda Tasseff
         Director, Investor Relations
         (904) 858-2639
         ltasseff@steinmart.com

(ANY) Glassware Delivers Solutions for Digital Learning Environments

Glassware 2.0 Future Proofs Texas School District’s Investment in 10,000+ Devices for a 1 to 1 Student Deployment

SAN JOSE, Calif., Feb. 4, 2015  — Sphere 3D Corporation (Nasdaq:ANY) today announced the availability of Glassware 2.0® for deployment in K-12 schools that are looking to deliver Windows application workspaces in support of a variety of devices—such as Android®, Chromebook, iPad®, OS X® and Windows RT®—and can work within an existing IT infrastructure or operate as a standalone solution.

“We tried traditional virtualization techniques but the specific applications we needed couldn’t virtualize or wouldn’t scale. With our Glassware 2.0 enabled Dell™ server, we were able to virtualize the applications we needed and future proof our investment in Chromebooks for our students,” commented Dustin Hardin, Director of Technology of New Caney ISD, a current Glassware customer. “Having the ability to securely deliver virtualized Windows-based applications to our students allows us to plan around our own technology roadmap instead of having to rely on multiple software vendors to release compatible versions or maintain support for existing versions already in use by our schools.”

According to the National Center for Education Statistics 2014 report there are approximately 49.8 million K-12 students, 98,300 public schools and 13,600 public school districts in the U.S alone. The majority of schools have labs filled with antiquated workstations and are migrating to or considering migrating to BYOD deployments or a 1 to 1 program with district-issued devices in student backpacks. The new devices are more mobile, less expensive, run on a variety of different operating systems, and far outnumber the workstations used before. For example, a school may migrate from 30 workstations running Windows XP to over 1,000 Chromebooks running the lightweight Chrome OS. In addition, a majority of these school districts face increased pressure to migrate from workstations to less expensive and more mobile devices.

Unfortunately, many of these devices don’t play well with current software which was written for a workstation dominated world and used for everything from digital learning to legislated standardized proficiency testing. Educational software companies have been overwhelmed by the need to deliver multiple platform support—writing a version of the application for iOS, a version for Chromebook and a version for Surface RT etc. In addition, many current applications require Internet access to sync with offsite data centers and use various plugins, Java and/or Flash software that is not supported by student devices, or will only work if security is disabled on students’ computers. Traditional virtualization solutions have not worked out because of their inability to virtualize many of these critical applications or deliver them economically or at scale.

Glassware 2.0 is delivered on one or multiple servers that can be placed at the school or the district’s data center. The Glassware 2.0 appliance allows school districts to quickly deliver Windows® workspaces, to most devices in use today, and further allows for secure access to portals for high stakes standardized testing, regardless of whether the portal is accessed by Internet Explorer, Safari, Chrome or a number of other browsers. Finally, Glassware provides licensing simplicity through Microsoft® embedded licensing on all Glassware appliances while enabling simple and flexible deployment options for IT administrators.

“Dustin, and the team at New Caney ISD, recognized that an increased access to technology will augment the learning experience for students in their district and moved forward to become one of the largest 1 to 1 Chromebook deployments in the K-12 segment with over 14,000 students with devices,” stated Peter Tassiopoulos, President of Sphere 3D. “We recognize that technology is quickly becoming part of the fabric of student life and are partnering with thought leaders and organizations like New Caney to pave the way for an immersive digital experience, both in the schools and from home.”

Glassware Demonstration Today

Dustin Hardin will be presenting and demonstrating Sphere 3D’s Glassware 2.0 virtualization technology today at the TCEA 2015 Convention & Exposition in Austin, Texas at 8:00a.m. CST and again at 12:00p.m. CST. TCEA is a member-based organization devoted to the use of technology in education. The 2015 conference is focused on passionate teachers, campus and district leaders gathering to share the latest trends and best practices for technology in education.

About Glassware 2.0 and Sphere 3D

Sphere 3D’s Glassware 2.0™ platform delivers virtualization of some of the most demanding applications in the marketplace today, making it easy to move applications from a physical PC or workstation to a virtual environment delivered to the user workspace on Chromebooks, tablets, Smartphones and a host of other devices.

Sphere 3D Corporation (Nasdaq:ANY) is a virtualization technology solution provider with a portfolio of products that address the complete data continuum from active data to data at rest. Dedicated to continue to lead through innovation, Sphere 3D enables the integration of virtual applications, virtual desktops, and storage into workflow, and allows organizations to deploy a combination of public, private or hybrid cloud strategies. Sphere 3D’s V3 converged infrastructure solutions include one of the industry’s first purpose-built appliances for virtualization and the Desktop Cloud Orchestrator management software for VDI. Overland Storage and Tandberg Data, wholly-owned subsidiaries of Sphere 3D, provide an integrated range of technologies and services for primary, nearline, offline, and archival data storage that make it easy and cost-effective to manage different tiers of information over the data lifecycle. For additional information, visit www.sphere3d.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, any increase in our cash needs; possible actions by customers, suppliers, competitors or regulatory authorities; other risks detailed in the Form F-4/A we filed with the SEC; and other risks detailed from time to time in our periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov). We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONTACT: Media Contact:
         Pattie Adams
         Director, Global Corporate Communications
         +1 408/283-4779
         padams@overlandstorage.com

         Investor Contact:
         MKR Group Inc.
         Todd Kehrli or Jim Byers
         +1 323/468-2300
         ovrl@mkr-group.com

(OHGI) Rollout of the Aishuo App in China

(APDNW) Demonstrates Multi-Modal In-Field Detection System

Reader Platform Offers On-the-Spot Mark Detection and Validation as Stand-Alone or Part of APDN’s digitalDNA(R) System, Making History in Authentication

(SPEX) Board Unanimously Rejects Unsolicited Proposal from Marathon Patent Group

Marathon Proposal Substantially Undervalues Spherix and is Not in the Best Interests of Stockholders

BETHESDA, Md., Feb. 3, 2015  — Spherix Incorporated (SPEX), an intellectual property development company committed to the fostering and monetization of intellectual property, today announced that its Board of Directors has considered and unanimously rejected an unsolicited proposal (the “Proposal”) received from Marathon Patent on January 15, 2015 indicating Marathon’s interest in acquiring Spherix in a stock-for-stock transaction valuing Spherix at a 15% premium above the recent market price of Spherix’s common stock. After a comprehensive review, conducted in consultation with its legal advisors, the Spherix Board concluded that the Proposal substantially undervalues Spherix, creates significant risks and uncertainties for the stockholders of Spherix, and is not in the best interests of the Company and its stockholders.

“After careful review and consideration, our Board of Directors has unanimously determined that Marathon’s unsolicited proposal substantially undervalues Spherix and does not reflect the value of the Company’s patent portfolio and its current business. We continue to execute our business plan and believe our assets put the company in its best position to be successful” said Anthony Hayes, CEO of Spherix.

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Investor Relations Contact:
Hayden IR
Brett Maas
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

Spherix Contact:
Phone: (703) 992-9325
Email: info@spherix.com
www.spherix.com

(CMLS) Conference Call to Discuss Q4 FY14 Operating Results

ATLANTA, Feb. 3, 2015  — Cumulus Media Inc. (Nasdaq:CMLS) will host a conference call on Monday, March 2^nd at 4:30 PM EST to discuss its fourth quarter and full year 2015 operating results. The call will be open to the general public on a listen-only basis.  A press release containing a summary of these results will be issued before the call at approximately 4:00 PM EST on March 2, 2015.

The conference call dial-in number for domestic callers is 877-830-7699, and international callers should dial 660-422-3366 for call access.

Please call five to ten minutes in advance to ensure that you are connected prior to the presentation.  The call also may be accessed via webcast at www.cumulus.com.

Following completion of the call, a replay can be accessed until 11:30 PM EDT on April 2, 2015. Domestic callers can access the replay by dialing 855-859-2056, replay code 76116091#. International callers should dial 404-537-3406 for conference replay access. 

About Cumulus Media:

Cumulus Media (Nasdaq:CMLS) combines high-quality local programming with iconic, nationally syndicated media, sports and entertainment brands in order to deliver premium choices for listeners, provide substantial reach for advertisers and create opportunities for shareholders. As the largest pure-play radio broadcaster in the United States, Cumulus provides exclusive content that is fully distributed through approximately 460 owned-and-operated stations in 90 U.S. media markets (including eight of the top 10), approximately 8,500 broadcast radio affiliates and numerous digital channels. Cumulus is well-positioned in the widening digital audio space through a significant stake in the Rdio digital music service, featuring over 30 million songs on-demand in addition to custom playlists and exclusive curated channels.  Cumulus is also the leading provider of country music and lifestyle content through its ‎NASH brand, which serves country fans nationwide through radio programming, NASH Country Weekly magazine, concerts, licensed products and television/video. For more information, visit www.cumulus.com

CONTACT: Collin Jones
         Investor Relations
         Cumulus Media Inc.
         404-260-6600

(APRI) Expands Exclusive Marketing License Agreement On Vitaros(R)

Apricus Eligible to Receive an Additional Upfront, Milestone Payment and a Double-Digit Royalty on Net Sales

SAN DIEGO, Feb. 3, 2015  — Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has further expanded its exclusive license agreement with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies (“Sandoz”), for the commercialization of Vitaros®, Apricus’ novel topical on-demand treatment for erectile dysfunction (“ED”). This amendment is in addition to the in-place collaboration established with Hexal AG in Germany in 2012, and the expansion of the cooperation in 2013 to include Austria, Belgium, Denmark, Finland, Iceland, Luxembourg, the Netherlands, Norway, Sweden and Switzerland. This expanded agreement includes Malaysia, Indonesia, the Philippines, Thailand, Taiwan, Vietnam, Hong Kong and Singapore (the “New Territory”).

In combination with the terms of the previously signed license agreements with Sandoz, Apricus is eligible to receive up to approximately $63.5 million in combined upfront, regulatory and sales milestone payments, which includes up to a total of $6.4 million in upfront and pre-commercialization payments, and a double-digit royalty rate for Vitaros.

“Leveraging our strong working relationships and expanding our existing Vitaros agreements with our collaboration partners is an on-going key initiative within Apricus,” said Richard Pascoe, Chief Executive Officer of Apricus. “Having recently introduced Vitaros in Germany, Belgium and Sweden, Sandoz has set an impressive pace with their launch performance to date, and as such, we are very pleased that they have elected to increase their commitment to Vitaros in these important markets outside of Europe.” Mr. Pascoe continued, “Moreover, we will continue to seek value creating partnerships in other available territories in an effort to bring this novel ED treatment to physicians and patients throughout the world.”

Vitaros is an exciting new entrant into the ED treatment market, offering a range of clear benefits that make it ideal for virtually any ED patient. Vitaros is a topical cream ED medication that delivers rapid onset (generally 5-15 minutes), a treatment duration of approximately 1 hour and an excellent safety profile. Vitaros’ local delivery provides a very attractive alternative for all patients, but particularly those with complications that preclude them from using the orally delivered systemic treatments or who prefer to not use the injectable forms of alprostadil.

According to the most recent estimates, the global ED market in 2013 was in excess of $5.5 billion annually. Vitaros has the potential to generate for Apricus over $215 million in future milestone payments, as well as additional potential royalty revenue on net product sales based upon double-digit royalty rates through its existing commercial partnerships. In addition, Apricus intends to leverage Vitaros through additional licensing efforts in key markets such a Japan and China in Asia and throughout Latin America.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ lead product, Vitaros^®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus’ marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus’ second-generation Vitaros Room Temperature Device is under development and is expected to enhance the product’s commercial value. The Vitaros trademark is registered or has pending applications for registration in certain countries and jurisdictions around the world. The mark is not registered in all of the countries mentioned above. Apricus recently commenced a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. Additionally, Apricus plans to initiate a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of male secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms. Apricus is currently seeking a strategic partner to fund development of Femprox^®, a product candidate for the treatment of female sexual interest/arousal disorder that completed an approximately 400-subject proof-of-concept study.

For further information on Apricus, visit http://www.apricusbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: references to the planned launches of Vitaros® in various countries by Sandoz; the potential for the product to achieve commercial success generally or in any specific territory; the size of the commercial opportunity for the product; and the timing of Phase 2 clinical trials for fispemifene. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: its ability to further develop its product Vitaros for the treatment of erectile dysfunction, such as the room temperature version of Vitaros, and its product candidates RayVa for the treatment of Raynaud’s phenomenon and fispemifene for the treatment of secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms in men, as well as the timing of such events; Apricus’ ability to carry out clinical studies for RayVa and fispemifene, as well as the timing and success of the results of such studies; potential adverse side effects or other safety risks associated with fispemifene and RayVa that could delay or preclude approval; Apricus’ dependence on its commercial partners to increase sales of Vitaros in various territories, and the potential for delays in the timing of commercial launches in additional countries; competition in the erectile dysfunction market and other markets in which Apricus and its partners operate; Apricus’ ability to obtain license partners for Vitaros; Apricus’ ability to obtain and maintain intellectual property protection for Vitaros, RayVa, fispemifene or any other product candidates; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to obtain the requisite governmental approval for Vitaros in the New Territory; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from Apricus.

CONTACT: Institutional Investors: Angeli Kolhatkar
         angeli@areciaadvisors.com
         Arecia Advisors
         (917) 387-44770

         Retail Investors: Chris Eddy, David Collins
         apri@catalyst-ir.com
         Catalyst Global
         (212) 924-9800

(REPH) Enters Into Common Stock Purchase Agreement With Aspire Capital

Recro Can Raise Up to $10 Million Over 2 Years

MALVERN, Pa., Feb. 3, 2015  — Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”). Under the new agreement, Recro has the right to sell up to $10 million in shares of common stock to Aspire Capital, subject to certain terms and conditions over a two-year period. The agreement represents an additional tool to provide the Company with additional capital and flexibility.

“While we remain focused on our on-going Dex-IN Phase II trial in acute pain following surgery, this financing provides us with additional financial flexibility in anticipation of our upcoming interim and top-line results for our on-going trial,” said Gerri Henwood, Recro Pharma’s President and Chief Executive Officer. “We believe that having ready access to capital provides us a stronger financial position as we continue our corporate, clinical and operational activities.”

Key terms under the common stock purchase agreement are:

• Recro will control the timing and amount of any sale of common shares to Aspire Capital;
• Aspire Capital has no right to require any sales by Recro but is obligated to make purchases as Recro directs, in accordance with the terms of the purchase agreement;
• There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement; and
• The purchase agreement may be terminated by Recro at any time, at its discretion, without any additional cost or penalty.

A complete and detailed description of the purchase agreement and related registration rights agreement will be set forth in the Company’s Current Report on Form 8-K filed today with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Recro Pharma, Inc.

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma’s lead product candidate, Dex-IN, is a proprietary intranasal formulation of dexmedetomidine and has completed multiple clinical trials in which Dex-IN was well tolerated. As Recro Pharma’s product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. If approved, Dex-IN would be the first and only approved acute pain drug in its class.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Recro Pharma’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Recro Pharma or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Recro Pharma as of the date of this press release and are subject to a number of risks, uncertainties, and other factors that could cause Recro Pharma’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Recro Pharma assumes no obligation to update any such forward-looking statements. Factors that could cause Recro Pharma’s actual results to materially differ from those expressed in the forward-looking statements set forth in this press release include, without limitation: the results and timing of the clinical trials of Dex-IN and any future clinical and preclinical studies; the ability to obtain and maintain regulatory approval of product candidates, and the labeling under any such approval; regulatory developments in the United States and foreign countries; the Company’s ability to raise future financing for continued development; the performance of third-party suppliers and manufacturers; the Company’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection; the successful commercialization of the Company’s product candidates; and the successful implementation of the Company’s strategy. In addition, the forward-looking statements in this press release should be considered together with the risks and uncertainties that may affect Recro Pharma’s business and future results included in Recro Pharma’s filings with the Securities and Exchange Commission at www.sec.gov.

CONTACT: Recro Pharma, Inc.
         Charles T. Garner
         Chief Financial Officer
         (484) 395-2425

         Media and Investors:
         Argot Partners
         Susan Kim
         (212) 600-1902
         susan@argotpartners.com